OpenNeedle Ask your own

Question explored with the scientific record

Answered on this page ↓

Ss31

Nov 16, 2026 · 5 sources used · OpenNeedle synthesis
Ss31 is almost certainly elamipretide, a mitochondria-targeted peptide studied for rare eye and muscle diseases. Nothing in this evidence shows it supports immunity or fights colds or flu.

The name matches elamipretide (SS31), a peptide aimed at mitochondria, the cell's power plants [5]. In aging mice it slowed and partly reversed vision decline, and eye drops worked about as well as injections [5]. That is a mouse study. It says nothing about immune support, and nothing about colds or flu.

The rest of the retrieved records are about other peptides entirely: influenza peptide vaccines in chickens [2], peptide-based diagnostic tests for H5N1 antibodies [3], and peptide inhibitors of viral fusion in cells [4]. None tested Ss31 in people for immune support. The one human-adjacent record is a peptide microarray that mapped antibody patterns after H1N1 infection versus vaccination [1], which is a diagnostic tool, not a supplement.

What was testedModelImmune or cold/flu outcome
Elamipretide (SS31) [5]Aging miceVision only; no immune endpoint
Replikin flu peptide vaccine [2]ChickensReduced virus detection in vaccinated birds
H5N1 peptide ELISA [3]Human seraDiagnostic, not treatment
Fusion-inhibitor peptides [4]CellsAntiviral in vitro only

If a seller is marketing "Ss31" for immune support, the burden is on them to show a human trial with a real outcome. No such trial appears here. The mouse vision work does not transfer to immunity, and the name similarity to other peptides is not evidence.

My call: Ss31 has no demonstrated role in immune support or cold/flu protection in humans; the only direct record is a mouse vision study. Confidence: moderate, because the retrieval is thin on Ss31 specifically.

Keep digging

Sources used 5

  1. H1N1 viral proteome peptide microarray predicts individuals at risk for H1N1 infection and segregates infection versus Pandemrix ® vaccination Immunology (2015) primary study Strong

    A peptide microarray covering the 2009 H1N1 proteome distinguished serum IgG epitope footprints between PCR-confirmed H1N1 infection and Pandemrix vaccination in a Swedish cohort, revealing exclusive vaccine-associated recognition of the HA epitope VEPGDKITFEATGNL.

    DOI: 10.1111/imm.12448
  2. Efficacy of a Replikin Peptide Vaccine Against Low-Pathogenicity Avian Influenza H5 Virus Avian Diseases (2009) Thin

    This study evaluates the efficacy of a synthetic replikin peptide vaccine against the low-pathogenicity avian influenza H5 virus in chickens, demonstrating its potential to protect against infection and reduce virus shedding.

    DOI: 10.1637/8892-042509-resnote.1
  3. H5N1-SeroDetect EIA and Rapid Test: a Novel Differential Diagnostic Assay for Serodiagnosis of H5N1 Infections and Surveillance Journal of Virology (2011) Thin

    Conserved H5N1 epitopes PB1-F2, M2e, and HA2 enable a peptide-based ELISA and rapid test (H5N1-SeroDetect) that accurately distinguishes H5N1 infection from seasonal influenza and vaccination, supporting large-scale, long-term surveillance.

    DOI: 10.1128/jvi.06023-11
  4. Peptide Inhibitors of Viral Membrane Fusion Medical Research Archives (2020) narrative review Strong

    Peptide inhibitors derived from viral fusion proteins can block membrane fusion and infection by lipid-enveloped viruses, with cholesterol or lipid conjugation often enhancing potency, though T-20 is the only clinically approved inhibitor.

    DOI: 10.18103/mra.v8i9.2244
  5. Treatment of age-related visual impairment with a peptide acting on mitochondria Disease Models & Mechanisms (2022) Thin

    Elamipretide (SS31), a mitochondria-targeted peptide, prevents and reverses age-related decline in photopic spatial vision in aging mice, with benefits preserved after withdrawal and effective via both systemic and ocular administration.

    DOI: 10.1242/dmm.048256

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question →